Guggenheim downgraded Outlook Therapeutics (OTLK) to Neutral from Buy.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics’ resubmission for wet AMD candidate rejected by FDA
- Navigating Trade Turbulence: Outlook Therapeutics’ Struggle with Global Trade Policies
- Outlook Therapeutics Reports Q3 2025 Earnings and Milestones
- Outlook Therapeutics reports Q3 adjusted EPS (44c) vs. (83c) last year
- OTLK Earnings Report this Week: Is It a Buy, Ahead of Earnings?